RxDoctor Payments Data

Syed Shah

Geriatric Medicine · Allen, TXNPI 1538115712

Payments from drug & device makers

$293in general payments, 2019–2025

Across 11 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$138
  • Novo Nordisk$34
  • Medtronic$32
  • AbbVie$19
  • Evoke Pharma, Inc.$18
  • Johnson & Johnson$15
  • plus $37 from 3 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293 in reported general payments places this provider in the 55th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$40,671
Medicare patients
149
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$79,852
OzempicSemaglutide49$52,341
FarxigaDapagliflozin Propanediol42$42,784
ProliaDenosumab14$24,792
LinzessLinaclotide15$19,595
Tresiba Flextouch U-100Insulin Degludec12$6,413
Humalog Kwikpen U-200Insulin Lispro15$6,390
Gabapentin140$2,548
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm23$2,089
Rosuvastatin Calcium233$2,082
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,948
Telmisartan50$1,316
Ezetimibe54$1,292
Levothyroxine Sodium136$1,290
Famotidine53$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$52,34149 claims
AstraZenecaFarxiga$14$42,78442 claims
AbbVieLinzess$19$19,59515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →